155 / 1851
Extended adjuvant therapy
0
3
6
9
12
15
18
21
24
Disease-free survival (%)
Months after randomization
1420
1420
1291
1367
1260
1324
1229
1292
1189
1243
1150
1209
1108
1163
1033
1090
No. at risk
Neratinib
Placebo
662
704
100
60
50
80
90
0
70
P-value = 0.009
HR (95% CI) = 0.67 (0.50–0.91)
97.8%
95.6%
93.9%
91.6%
Neratinib
Placebo
2.3%
Intention-to-treat population
Chan et al. Lancet Oncol 2016
32